Tagged: ALK inhibitors

Figure 2: Overview of brigatinib’s and alectinib’s mechanisms of action. Receptor targets of each drug are depicted through the cell membrane and the following pathways and pathophysiological motives affected are depicted from the cell surface to the nucleus. Alectinib acts through ALK and RET, involved mainly in survival and proliferation, while brigatinib acts also through ALK and FLT3, IGF1R, and EGFR, signaling through overlapping intracellular mechanisms affecting cell survival and proliferation, metastasis, apoptosis and migration. Bibliographical validation information of interactions on the predicted mechanisms of action are shown in Supplementary data (Supplementary Table 1).

Trending with Impact: Machine Learning Used to Compare ALK Inhibitors

Researchers use a computer simulated modeling system to highlight the strengths and weaknesses of two... read more

March 4, 2021